News

ALLG News Edition 9

September’s Blood Cancer Awareness Month is vital in raising awareness of blood cancer and the importance of clinical trial research in improving treatments, survival rates and quality of life for patients. Through this edition find out how ALLG continues to drive blood cancer research forward to bring new and innovative cancer therapies to patients across Australia and New Zealand.

In ALLG New Edition 9, you can also read about two significant international trial collaborations, our ALLG HD10 /HD21 with the German Study Group and our AMLM26 INTERCEPT, soon to open in the US at the MD Anderson Cancer Center. Discover the key teams behind the scenes who with our researchers to develop new trial concepts and pursue Better treatments…Better lives for patients.

You can read ALLG News Edition 9 here.

ALLG News Edition 8

Patients are at the centre of everything ALLG does, and our Consumer Representative Panel are key to ALLG clinical trials. Each of our consumer representatives have lived cancer experience and provide the essential patient voice to our clinical trial research. In this edition find out about their stories, what survivorship means to them, and how they impact ALLG trials.

In ALLG News Edition 8, you can also read about our impactful ALLG ALL09 SUBLIME clinical trial. Chief Investigator Associate Professor Matthew Greenwood recently presented the final results of this trial at the European Hematology Association Meeting in Madrid, 13-16 June. The ALL09 trial aimed to find a better way to treat adolescents and young adults (AYA) with acute lymphoblastic leukaemia (ALL) by incorporating a new immunotherapy treatment called blinatumomab into the standard treatment.

You can read ALLG News Edition 8 here.

ALLG News Edition 7

In this edition, we congratulate our nine ALLG members who had their ALLG clinical trial abstracts accepted for oral and poster presentation on the world stage at the American Society of Hematology Annual Meeting and Exposition (ASH 23). This leading haematology event brings together over 35,000 delegates from across the globe.

Find out more about our advancements in myeloma treatments through our impactful MM23 SeaLand trial and MM26 NORM platform trial and how ALLG research is positively impacting patients with blood cancer. Read about Ivan’s Bubalo’s experience and what ALLG’s clinical trial research means to him and his family.

You can read ALLG News Edition 7 here.

 ALLG News Edition 6

As we wrap up our 50th Anniversary year, discover how ALLG is building on the legacy of our five decades of impact as we look to accelerate our research and impact. Find out how targeted therapies and other innovations are improving treatments and outcomes for patients with blood cancer.

In ALLG News Edition 6 read about how ALLG is leading the way in technological advancements and new treatments, including immunotherapies, CAR-T cell therapy and the use of artificial intelligence systems to aid research to support better patient outcomes.

You can read ALLG News Edition 6 here.

ALLG News Edition 5

This bumper edition of ALLG News for our 50th year we feature our “Five decades of impact” in clinical trial research for better treatments, better lives. We also feature ground breaking clinical trial HD10 for Advanced-stage Hodgkin lymphoma that provided the “best results we have ever seen in young patients from 18 to 60 years”. You can also read inspiring stories from clinical trial participants, Emma and Bianca, who are back to living their normal lives after participating on ALLG trials for their blood cancer. Read these stories, and more, in this newsletter.

You can read ALLG News Edition 5 here.

ALLG News Edition 4

Our Laboratory Science research is helping determine which patients benefit from targeted therapy for their blood cancer. You can read about this in our latest newsletter that also includes a heart warming story from Brian who recently celebrated his 70th thanks to being on a lifesaving ALLG clinical trial 15 years ago for his chronic myeloid leukaemia. We also feature some of our latest Life Members of ALLG and a special message from our CEO about ALLG’s five decades of impact, and more, in this newsletter.

You can read ALLG News Edition 4 here.

ALLG News Edition 3

Our teletrials allow greater access for patients living in rural and regional areas of Australia and New Zealander, to participate on clinical trials; including patients just like Cairns (Australia) resident Vesselin (Vess) Petkov, an anaesthetist who joined an ALLG clinical trial for the treatment of his Mantle Cell Lymphoma. You can read Vess’ story, and more, in this newsletter.

You can read ALLG News Edition 3 here.

ALLG News Edition 2

Our international clinical trial collaborations bring new treatments to Australians and New Zealanders; including patients just like New Zealander Hemi Frires, a Royal New Zealand Air Force pilot who joined an ALLG clinical trial for the treatment of his Hodgkin Lymphoma. You can read Hemi’s story, and more, in this newsletter.

You can read ALLG News Edition 2 here.

ALLG News Edition 1

The first ever Australasian Leukaemia and Lymphoma Group (ALLG) quarterly newsletter – ALLG News. ALLG launched our community newsletter in September 2022 during Blood Cancer Awareness Month, a critical time to raise awareness of blood cancers such as leukaemia, lymphoma and myeloma.

You can read ALLG News Edition 1 here.